BACKGROUND AND OBJECTIVES: Portopulmonary hypertension (PoPH) is a rare complication of portal hypertension associated with poor survival. Scarce data is available on predictors of survival in PoPH with conflicting results. We sought to characterize the outcomes and variables associated with survival in a large cohort of patients with PoPH in an American population of patients. STUDY DESIGN AND METHODS: We identified PoPH patients from the Cleveland Clinic Pulmonary Hypertension Registry between 1998 and 2019. We collected prespecified data, particularly focusing on hepatic and cardiopulmonary assessments and tested their effect on long-term survival. RESULTS: Eighty patients with PoPH with a mean ± SD age of 54 ± 10 years, (54% females) were included in the analysis. The median Model for End-Stage Liver Disease with sodium (MELD-Na) score was 13.0 (10.0-18.0) at PoPH diagnosis. World Health Association functional class III-IV was noted in 57%. Mean pulmonary arterial pressure was 47 ± 10 mmHg and pulmonary vascular resistance 6.0 ± 2.8 Woods units. A total of 63 (78.5%) patients were started on pulmonary arterial hypertension (PAH)-specific treatment during the first 6 months of diagnosis. Survival rates at 1-, 3- and 5-year were 77, 52 and 34%, respectively. Cardiopulmonary hemodynamics as well as PAH-specific treatment did not affect survival. In the multivariable model, MELD-Na, resting heart rate and the presence of hepatic encephalopathy were independent predictors of survival. CONCLUSION: PoPH patients have poor 5-year survival which is strongly associated to the severity of underlying liver disease and not to the hemodynamic severity of PoPH; therefore efforts should be focused in facilitating liver transplantation for these patients.
BACKGROUND AND OBJECTIVES: Portopulmonary hypertension (PoPH) is a rare complication of portal hypertension associated with poor survival. Scarce data is available on predictors of survival in PoPH with conflicting results. We sought to characterize the outcomes and variables associated with survival in a large cohort of patients with PoPH in an American population of patients. STUDY DESIGN AND METHODS: We identified PoPH patients from the Cleveland Clinic Pulmonary Hypertension Registry between 1998 and 2019. We collected prespecified data, particularly focusing on hepatic and cardiopulmonary assessments and tested their effect on long-term survival. RESULTS: Eighty patients with PoPH with a mean ± SD age of 54 ± 10 years, (54% females) were included in the analysis. The median Model for End-Stage Liver Disease with sodium (MELD-Na) score was 13.0 (10.0-18.0) at PoPH diagnosis. World Health Association functional class III-IV was noted in 57%. Mean pulmonary arterial pressure was 47 ± 10 mmHg and pulmonary vascular resistance 6.0 ± 2.8 Woods units. A total of 63 (78.5%) patients were started on pulmonary arterial hypertension (PAH)-specific treatment during the first 6 months of diagnosis. Survival rates at 1-, 3- and 5-year were 77, 52 and 34%, respectively. Cardiopulmonary hemodynamics as well as PAH-specific treatment did not affect survival. In the multivariable model, MELD-Na, resting heart rate and the presence of hepatic encephalopathy were independent predictors of survival. CONCLUSION: PoPH patients have poor 5-year survival which is strongly associated to the severity of underlying liver disease and not to the hemodynamic severity of PoPH; therefore efforts should be focused in facilitating liver transplantation for these patients.
Authors: Sasiharan Sithamparanathan; Arun Nair; Logan Thirugnanasothy; J Gerry Coghlan; Robin Condliffe; Konstantinos Dimopoulos; Charlie A Elliot; Andrew J Fisher; Sean Gaine; J Simon R Gibbs; Michael A Gatzoulis; Clive E Handler; Luke S Howard; Martin Johnson; David G Kiely; James L Lordan; Andrew J Peacock; Joanna Pepke-Zaba; Benjamin E Schreiber; Karen K K Sheares; Stephen J Wort; Paul A Corris Journal: J Heart Lung Transplant Date: 2016-12-31 Impact factor: 10.247
Authors: Olivier Sitbon; Jaume Bosch; Emmanuelle Cottreel; Denes Csonka; Pascal de Groote; Marius M Hoeper; Nick H Kim; Nicolas Martin; Laurent Savale; Michael Krowka Journal: Lancet Respir Med Date: 2019-06-06 Impact factor: 30.700
Authors: Rebecca Deroo; Eric Trépo; Tom Holvoet; Michel De Pauw; Anja Geerts; Xavier Verhelst; Isabelle Colle; Hans Van Vlierberghe; Michael B Fallon; Sarah Raevens Journal: Hepatology Date: 2020-10-19 Impact factor: 17.425
Authors: Michael J Krowka; Dave P Miller; Robyn J Barst; Darren Taichman; Raed A Dweik; David B Badesch; Michael D McGoon Journal: Chest Date: 2011-07-21 Impact factor: 9.410
Authors: M Castro; M J Krowka; D R Schroeder; K C Beck; D J Plevak; S R Rettke; D A Cortese; R H Wiesner Journal: Mayo Clin Proc Date: 1996-06 Impact factor: 7.616
Authors: Maria Lazaro Salvador; Carlos A Quezada Loaiza; Luis Rodríguez Padial; Joan A Barberá; Manuel López-Meseguer; Raquel López-Reyes; Ernest Sala-Llinas; Sergio Alcolea; Isabel Blanco; Pilar Escribano-Subías Journal: Intern Med J Date: 2021-03 Impact factor: 2.048
Authors: Hilary M DuBrock; Rodrigo Cartin-Ceba; Richard N Channick; Steven M Kawut; Michael J Krowka Journal: Chest Date: 2020-08-13 Impact factor: 9.410
Authors: Cerise Kleb; Manik Aggarwal; Adriano R Tonelli; Mattie White; Ruishen Lyu; Cristiano Quintini; Koji Hashimoto; Charles Miller; Jacek Cywinski; Bijan Eghtesad; Maan Fares; K V Narayanan Menon Journal: Transplant Direct Date: 2022-10-07